Skip to main content

Table 2 Clinical characteristics

From: FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases

Patients No Sex/Age (y) Previous treatment Response to FCR Response to RIT Follow up (mo) since RIT
1 F/68 CHOP/R, radiotherapy CR CR 50 alive in CR
2 F/66 Radiotherapy, CHOP/R CR CR 34 alive in CR
3 F/57 CHOP/R PR CR 44 alive in CR
4 F/67 CHOP/R, radiotherapy CR CR 13 dead in CR
5 M/46 CHOP/like, ASCT, IFN maintenance for 24 months PR CR 28 alive in CR
6 F/61 MACOPB/R CR CR 39 alive in CR
7 M/69 CHOP,FM/R, Cy Dex/R CR CR 30 dead in CR
8 M/57 Chlorambucil, MACOPB/R CR CR (t-MDS) 32 dead in CR
9 F/77 Chlorambucil, radiotherapy CR CR 44 alive in CR
  1. CHOP: cyclophosfamide, doxorubicin, vincristine, prednisone; R: Rituximab; MACOPB: Methotrexate, Doxorubicin, cyclophoshamide, vincristine, prednisone, bleomycin,; ASCT: autologous stem cell transplantation; IFN: alpha interferon, FM: fludarabine, mitoxantrone; Cy Dex: cyclophosphamide, dexamethasone; t-MDS: treatment-related myelodysplastic syndrome